HCW Biologics Inc. announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, in patients with solid tumors who failed at least two prior lines of therapy. Data from this study was presented at the 38(th) Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") by Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women's Health at the University of Minnesota who serves as a Principal Investigator of this trial. Highlights of data presented at SITC include: HCW9218 w was administered subcutaneously once every three weeks for up to six cycles at dose levels 0.25 mg/kg (DL1), 0.5 mg/kg (DL2), 0.8 mg/kg (DL3) or 1.2 mg/kg (DL4).

In addition, the company believe, perhaps even more importantly, their extensive correlative studies provide valuable evidence that will inform Phase 2 clinical studies in cancer indications. With these strong results as a foundation, the company believe the company will be in a position to pivot to initiate first Phase 2 clinical trial this year. The company is also enrolling patients in a Company-sponsored Phase 1b/2 clinical trial to evaluate HCW9218 in chemo-refractory/chemo-resistant advanced pancreatic cancer.